Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGHID 12333 Study
PACTR202402687748210Phase 1Not yet recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in cancer, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Plasma AUC of dihydroartemisinin. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
artesunate
03
Conditions
cancer
Beyond the preview
Go deeper on PACTR202402687748210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402687748210.